---

Partnership Increases Investment and Drug Candidates Licensing and Partnership Opportunities for Biotech and Biopharma Companies

---

Press release:  PRWeb

NEW YORK (PRWEB) JANUARY 30, 2023

BioNeex (http://www.bioneex.com), the biopharma industry’s first research and development (R&D) open exchange platform for drug candidates licensing, co-development partnerships, and investments, announced today it is partnering with TVM Capital Life Science (http://www.tvm-lifescience.com), a leading international venture capital firm focused on investment in life sciences innovation, to launch BioNeex Forum. The partnership is designed to bring together biotech and biopharma companies, as well as research institutions, with venture capital firms to increase investment and drug candidates licensing and co-development partnership opportunities.

BioNeex Forum will help preclinical and early clinical-stage biotech and biopharma companies identify business development opportunities to support their drug development pipeline. The forum is an expansion of the company’s successful BioNeex Interviews, a series of sit-downs with CEOs of early-stage biotech companies with their drug candidates listed on the BioNeex platform. Well received by the industry, these leadership conversations help match biotech companies with potential partners, investors, and other external stakeholders. BioNeex Forum events planned for 2023 will bring together more companies and potential investors in one place throughout the year.

“The BioNeex exchange platform represents a valuable tool in our portfolio company selection process. It provides access to drug candidates, and more importantly, enables a direct connection to decision makers at relevant biotech organizations,” said Dr. Sascha Berger, General Partner of TVM Capital Life Science. “We look forward to introducing our unique early-stage investment approach and related criteria as part of the BioNeex Forum. Bringing together potential partners and encouraging new channels for biotech investment helps increase exposure for innovative drug candidates, giving them the best chance to reach late-stage clinical development and ultimately become novel medicines.”

With a 35-year track record of investing globally and more than $2 billion raised, TVM Capital Life Science provides venture capital to the international pharmaceutical, biopharmaceutical, and medical technology industries. For early-stage investments, the firm fully funds promising drug candidates to clinical proof-of-concept in designated special purpose vehicles, so-called product focused companies, and works with Eli Lilly and Company to assist in the implementation of a drug development plan, resulting in high-quality data packages to help determine proof of concept. Biotech companies can now connect directly with TVM Capital Life Science via BioNeex’s two-sided marketplace and learn more about their investment opportunities through the BioNeex Forum.

“The BioNeex team is elated to be working alongside TVM Capital Life Science. It is a testament to the continued value the exchange platform brings to the industry,” Dr. Smbat Rafayelyan, Founder & CEO of BioNeex. “By combining the power of science and relationships, our goal is to continue to be the go-to marketplace for development-stage biotech, biopharma companies, and venture capital firms to secure licensing, co-development partnership, and investment deals.”

The BioNeex exchange is a secure online platform where biotech, biopharma companies, and research institutions list drug candidates available for licensing, co-development partnerships, and investment. The two-sided marketplace allows biopharma, biotech companies, research institutions, and venture capital firms to connect directly, helping create more R&D licensing, co-development partnership, and investment opportunities. BioNeex offers the most complete, accurate and up-to-date data in the biopharma industry that is shared directly from drug candidate developers, with more than half of the world’s largest biopharmaceutical companies using it. The exchange is highly focused on novel drug candidates – new molecular entities (NMEs) that are first-in-class, best-in-class.

About BioNeex

BioNeex is the first R&D open exchange platform in the biopharma industry, a two-sided marketplace that directly connects biotech, biopharmaceutical companies, research institutions and venture capital firms to facilitate licensing and co-development partnership deals for preclinical and clinical-stage drug candidates, as well as investments. The marketplace enables potential licensing and co-development partners and investors to access the most complete, accurate, and up-to-date drug candidate data, posted directly by drug candidate developers, and to contact them directly with one click. For more information, please visit: http://www.bioneex.com

About TVM Capital Life Science

TVM Capital Life Science provides venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 35-years of transatlantic investment track record and more than $2 billion raised. With its advisory, corporate finance and investment teams in Montreal and Munich, the TVM Capital Life Science team provides investors, as well as entrepreneurs and innovation-seeking biopharmaceutical companies, access to global life science innovation and provides paths for successful tech transfer and commercialization for the benefit of patients and investors alike.

The TVM Capital Life Science team looks back on more than 140 investments and over 100 exits, including more than 45 initial public offerings on all major U.S. and European stock exchanges. The team has gained unrivaled international investment and business development experience with its track record of dedicated board work, significant contribution to global networks in the world of life science research and product development, and a direct knowledge of the local markets. More information: http://www.tvm-lifescience.com

Media Contact

Dr. Smbat Rafayelyan, Founder & CEO, BioNeex | [email protected]
Dr. Sascha Berger, General Partner, TVM Capital Life Science | [email protected]